1. Mechanism and spectrum of action, side effects, contraindications and indications for prescribing broncholitics (metilxantines) Interaction 2. Mechanism and spectrum of action, side effects, contraindications and indications for prescribing steroidal antiinflammatory drugs. Interaction.

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

I now have comprehensive information from both Goodman & Gilman's and Fishman's Pulmonary Diseases. I have detailed content on methylxanthines. For corticosteroids, I need to draw from what I've collected and my knowledge base since the DB queries for that topic didn't return the most relevant pharmacology content. Let me compile the full answer now.

1. Bronchodilators — Methylxanthines

Representative Drugs

Theophylline (oral slow-release, IV solution)
Aminophylline (ethylenediamine salt of theophylline; IV)
Dyphylline (synthetic derivative; oral)
Caffeine (preferred for apnea of prematurity)

Mechanism of Action

Methylxanthines exert bronchodilation and anti-inflammatory effects through several molecular mechanisms:

1. Phosphodiesterase (PDE) Inhibition — Theophylline is a nonselective PDE inhibitor. PDEs hydrolyze cAMP and cGMP to inactive 5'-monophosphates. PDE inhibition raises intracellular cAMP and cGMP, leading to airway smooth-muscle relaxation and bronchodilation. PDE3 inhibition is the primary driver of bronchodilation. However, inhibition is relatively weak at clinically relevant concentrations.

2. Adenosine Receptor Antagonism — At therapeutic concentrations, theophylline antagonizes A1, A2, and A3 adenosine receptors. Adenosine causes bronchoconstriction by promoting mast cell degranulation (histamine/leukotriene release). Blocking adenosine receptors reduces bronchoconstriction and activates histone deacetylase (HDAC), inhibiting transcription of pro-inflammatory cytokines. This is considered the dominant mechanism at clinically achievable serum concentrations.

3. HDAC2 Activation (Anti-inflammatory) — Theophylline (even at low doses, 1–5 mg/L) activates HDAC2 in bronchial epithelial cells and macrophages via inhibition of phosphoinositide-3-kinase-δ (PI3K-δ). HDAC2 is the enzyme recruited by glucocorticoid receptors to switch off activated inflammatory genes — theophylline thus enhances the anti-inflammatory effects of corticosteroids synergistically.

4. NF-κB Inhibition — Theophylline prevents nuclear translocation of NF-κB, reducing expression of inflammatory genes (at higher concentrations).

5. Apoptosis of Inflammatory Cells — Promotes apoptosis of eosinophils (relevant in asthma) and neutrophils (relevant in COPD), limiting perpetuation of chronic inflammation. Also induces T-lymphocyte apoptosis via PDE inhibition.

6. IL-10 Release — Theophylline increases secretion of IL-10 (broad anti-inflammatory cytokine whose production is reduced in asthma/COPD).

"Methylxanthines have direct bronchodilator and immunomodulatory properties... Multiple molecular mechanisms have been proposed, including competitive adenosine receptor inhibition, nonselective PDE inhibition, GABA receptor modulation, activation of ryanodine-sensitive calcium channels, activation of HDACs, reduced expression of inflammatory genes, promotion of neutrophil and T-lymphocyte apoptosis, and inhibition of PARP-1." — Fishman's Pulmonary Diseases and Disorders

Spectrum of Action / Pharmacological Effects

Bronchial smooth-muscle relaxation (bronchodilation)
Enhanced mucociliary transport
Inhibition of mediator release (mast cells)
Suppression of permeability edema
Decreased pulmonary hypertension
Increased right ventricular ejection fraction
Improved diaphragmatic contractility
Central stimulation of ventilation

Pharmacokinetics

Rapidly and completely absorbed orally
Wide interindividual variation in clearance due to hepatic metabolism (primarily CYP1A2)
Therapeutic range: 5–15 mg/L (current NAEPP recommendation; older range 10–20 mg/L is no longer standard)
Dose individualization required; plasma monitoring at steady state (3–5 days after initiation or dose change)

Indications

Asthma (chronic): Add-on controller at GINA Step 3–4 (low-dose theophylline) in patients inadequately controlled on ICS alone; Step 5 add-on to dual therapy. Also an alternative for mild persistent asthma.
COPD: Alternative/add-on maintenance bronchodilator when inhaled anticholinergics and β₂ agonists are insufficient, or when cost is limiting.
Apnea of prematurity: Caffeine (preferred methylxanthine).
Acute severe asthma: IV aminophylline reserved for patients who fail or are intolerant of β₂ agonists (less effective than nebulized β₂ agonists).

Side Effects

Side Effect	Proposed Mechanism
Nausea, vomiting, diarrhea, headache	PDE4 inhibition
Gastric discomfort, increased acid secretion	PDE4 inhibition
Diuresis	A₁ receptor antagonism
Irritability, insomnia, behavioral disturbance (in children)	—
Cardiac arrhythmias	PDE3 inhibition + A₁ receptor antagonism
Seizures (at very high levels >40 mg/L)	Central A₁ receptor antagonism

"Unwanted effects of theophylline are usually related to plasma concentration and tend to occur at Cp greater than 15 mg/L." — Goodman & Gilman's

GI and CNS "caffeine-like" effects appear at >15 mg/L; ventricular arrhythmias and seizures are more likely at >40 mg/L, but can occur at lower levels.

Contraindications

Active peptic ulcer disease (increases acid secretion)
Seizure disorders (lowers seizure threshold at toxic concentrations)
Severe cardiac arrhythmias
Hypersensitivity to xanthines
Roflumilast (a selective PDE4 inhibitor): contraindicated in severe hepatic impairment (Child-Pugh B/C)

Drug Interactions

Agents that INCREASE theophylline levels (CYP1A2 inhibitors → toxicity risk):

Macrolide antibiotics (erythromycin, clarithromycin)
Fluoroquinolones (ciprofloxacin)
Cimetidine
Fluvoxamine, fluconazole, ketoconazole

Agents that DECREASE theophylline levels (CYP1A2 inducers → loss of efficacy):

Rifampicin
Phenytoin, barbiturates
Antivirals
Tobacco smoke (polycyclic aromatic hydrocarbons)

Disease states increasing theophylline levels:

Hepatic cirrhosis, viral hepatitis
Congestive heart failure, cor pulmonale (passive hepatic congestion)
Acute viral illness / pneumonia (interferon induction)
Hypothyroidism; elderly (≥65 years)

Disease states decreasing theophylline levels:

Hyperthyroidism
Cystic fibrosis

— Fishman's Pulmonary Diseases and Disorders; Goodman & Gilman's Pharmacological Basis of Therapeutics

2. Steroidal Anti-Inflammatory Drugs (Glucocorticoids)

Representative Drugs

Systemic: Prednisone, prednisolone, methylprednisolone, dexamethasone, hydrocortisone, betamethasone

Inhaled (ICS — for asthma/COPD): Beclomethasone, budesonide, fluticasone, mometasone, ciclesonide

Mechanism of Action

Glucocorticoids bind to cytoplasmic glucocorticoid receptors (GRs), which translocate to the nucleus and exert effects through two pathways:

1. Transrepression (anti-inflammatory — primary therapeutic mechanism):

The GR complex inhibits pro-inflammatory transcription factors, primarily NF-κB and AP-1, preventing transcription of cytokines (IL-1, IL-2, IL-6, TNF-α), chemokines, adhesion molecules, and enzymes (COX-2, iNOS, phospholipase A2).
GR recruits HDAC2 to active inflammatory gene promoter sites, deacetylating histones and silencing inflammatory gene expression. (This is the same HDAC2 that theophylline activates — their combination is synergistic.)

2. Transactivation (many metabolic and adverse effects):

GR binds glucocorticoid response elements (GREs) in DNA → upregulates anti-inflammatory genes (lipocortin-1/annexin A1, which inhibits phospholipase A2; IL-10; secretory leukocyte protease inhibitor).
Also drives gluconeogenesis, protein catabolism, fat redistribution (metabolic side effects).

Key anti-inflammatory cellular effects:

Inhibit synthesis and release of prostaglandins and leukotrienes (via phospholipase A2 inhibition → less arachidonic acid release)
Reduce vascular permeability and edema
Inhibit recruitment and activation of eosinophils, mast cells, T-lymphocytes, macrophages, and dendritic cells
Reduce mucus secretion and airway remodeling
Stabilize lysosomal membranes

Spectrum of Action / Pharmacological Effects

Respiratory: Reduce airway inflammation, hyperresponsiveness, and mucus secretion in asthma; reduce exacerbations in COPD
Immunosuppression: Blunt both humoral and cell-mediated immunity; reduce lymphocyte proliferation and antibody production
Broad anti-inflammatory: Used in virtually all inflammatory, allergic, and autoimmune conditions
Metabolic: Gluconeogenesis, protein catabolism, lipolysis, fat redistribution

Indications

Asthma: ICS is first-line controller for all persistent asthma (step 2+); systemic steroids for acute exacerbations
COPD: ICS (with LABA) for severe disease; short systemic courses for exacerbations
Allergic rhinitis, urticaria, anaphylaxis
Rheumatoid arthritis, systemic lupus erythematosus, vasculitis, polymyalgia rheumatica
Inflammatory bowel disease (Crohn's, ulcerative colitis)
Organ transplant rejection prophylaxis
Adrenal insufficiency (replacement therapy)
Cerebral edema (dexamethasone)
Septic shock (low-dose hydrocortisone in refractory cases)
Dermatological: Eczema, psoriasis, contact dermatitis (topical)
Hematological: Autoimmune hemolytic anemia, ITP

Side Effects

Short-term / high-dose:

Hyperglycemia / steroid-induced diabetes
Sodium retention, hypertension, hypokalemia
Fluid retention / edema
Mood changes, euphoria, insomnia, psychosis
Increased susceptibility to infection (immunosuppression)
Peptic ulceration (especially with NSAIDs)
Acute adrenal suppression on rapid withdrawal

Long-term / chronic use:

Cushing's syndrome: Central obesity, moon face, buffalo hump, striae, skin atrophy, bruising
Osteoporosis (inhibit osteoblasts, increase osteoclast activity; decrease Ca²⁺ absorption)
Adrenal suppression / HPA axis suppression → adrenal insufficiency on withdrawal
Myopathy (proximal muscle weakness)
Growth retardation in children
Cataracts (posterior subcapsular), glaucoma
Avascular (aseptic) necrosis of the femoral head
Impaired wound healing

ICS-specific (topical) side effects:

Oropharyngeal candidiasis (use spacer, rinse mouth after)
Dysphonia (hoarseness)
Minimal systemic absorption at standard doses; high doses can suppress HPA axis

Contraindications

Absolute: Systemic fungal infections (without antifungal cover); live vaccines in immunosuppressed patients
Relative / use with caution:
- Active peptic ulcer disease
- Diabetes mellitus (worsen glycemic control)
- Hypertension, congestive heart failure, edematous states
- Osteoporosis (especially postmenopausal women)
- Active tuberculosis or untreated infections
- Psychosis / psychiatric disorders
- Pregnancy (Category C; avoid high-dose systemic use, especially 1st trimester)
- Glaucoma / cataracts

Never abruptly discontinue after prolonged use — taper slowly to prevent acute adrenal insufficiency. Minimize duration of systemic use whenever possible.

Drug Interactions

Interaction	Effect
NSAIDs	Increased risk of peptic ulceration and GI bleeding
Antidiabetics (insulin, metformin)	Antagonism — steroids raise blood glucose
Antihypertensives, diuretics	Antagonism — steroids cause Na⁺ retention, raise BP; potassium-wasting diuretics worsen hypokalemia
CYP3A4 inducers (rifampicin, phenytoin, barbiturates)	Decreased steroid levels (reduced efficacy)
CYP3A4 inhibitors (ketoconazole, erythromycin)	Increased steroid levels (increased toxicity)
Warfarin / anticoagulants	Variable — may increase or decrease effect; monitor INR
Live vaccines	Risk of disseminated infection; contraindicated
Theophylline	Synergistic anti-inflammatory (via HDAC2 activation)
Aspirin / salicylates	Increased GI toxicity; steroids lower salicylate levels

Theophylline–Corticosteroid Synergy

A critical pharmacological interaction: theophylline activates HDAC2 (via PI3K-δ inhibition), the same enzyme that corticosteroids recruit to silence inflammatory genes. The combination is synergistic — low-dose theophylline restores steroid sensitivity in corticosteroid-resistant COPD patients and enhances ICS efficacy in asthma. This is the key rationale for combining low-dose theophylline with ICS in step 3–5 asthma.

Sources: Goodman & Gilman's The Pharmacological Basis of Therapeutics | Fishman's Pulmonary Diseases and Disorders, 2-Volume Set

Give me short and point vise answer

1. Methylxanthines (Theophylline, Aminophylline, Dyphylline)

Mechanism of Action

PDE inhibition → ↑cAMP/cGMP → airway smooth muscle relaxation
Adenosine receptor antagonism (A1, A2, A3) → blocks bronchoconstriction + mast cell degranulation
HDAC2 activation → silences inflammatory genes (synergy with steroids)
NF-κB inhibition → ↓inflammatory gene transcription
Promotes apoptosis of eosinophils & neutrophils
↑IL-10 release → broad anti-inflammatory effect

Spectrum of Action

Bronchodilation
Anti-inflammatory & immunomodulatory
Stimulates respiratory drive (central)
Improves diaphragmatic contractility
Enhances mucociliary clearance

Indications

Chronic asthma (add-on, Step 3–5)
COPD (add-on/alternative bronchodilator)
Apnea of prematurity (caffeine preferred)
Acute severe asthma (IV aminophylline — only if β₂ agonists fail)

Side Effects

GI: Nausea, vomiting, diarrhea, ↑acid (PDE4 inhibition)
CNS: Headache, insomnia, irritability, seizures (toxic levels)
CVS: Tachycardia, arrhythmias (PDE3 + A1 antagonism)
Renal: Diuresis (A1 antagonism)
Children: Behavioral disturbance, learning difficulties

Most side effects occur at plasma levels >15 mg/L; seizures/arrhythmias at >40 mg/L

Contraindications

Active peptic ulcer
Seizure disorders
Severe cardiac arrhythmias
Hypersensitivity to xanthines

Drug Interactions

↑Theophylline levels (toxicity risk):

Erythromycin, ciprofloxacin, cimetidine, fluvoxamine, ketoconazole

↓Theophylline levels (loss of efficacy):

Rifampicin, phenytoin, barbiturates, tobacco smoke

Disease states ↑levels: Heart failure, cirrhosis, viral illness, hypothyroidism, elderly

2. Steroidal Anti-Inflammatory Drugs (Glucocorticoids)

Mechanism of Action

Bind cytoplasmic glucocorticoid receptor (GR) → GR translocates to nucleus
Transrepression: GR inhibits NF-κB & AP-1 → ↓cytokines (IL-1, IL-6, TNF-α), ↓COX-2, ↓iNOS
HDAC2 recruitment → deacetylates histones → silences inflammatory genes
Phospholipase A2 inhibition (via lipocortin-1) → ↓arachidonic acid → ↓prostaglandins & leukotrienes
Reduce vascular permeability, eosinophil/mast cell/T-cell recruitment

Spectrum of Action

Anti-inflammatory (broadest spectrum of any drug class)
Immunosuppressive
Anti-allergic
Metabolic (gluconeogenesis, protein catabolism, fat redistribution)

Indications

Asthma (ICS = first-line controller; systemic = acute exacerbations)
COPD exacerbations
Rheumatoid arthritis, SLE, vasculitis
IBD (Crohn's, ulcerative colitis)
Allergic rhinitis, anaphylaxis, urticaria
Adrenal insufficiency (replacement)
Cerebral edema (dexamethasone)
Organ transplant rejection
Autoimmune hemolytic anemia, ITP

Side Effects

Short-term:

Hyperglycemia
HTN, Na⁺ retention, hypokalemia, edema
Mood changes, insomnia, psychosis
Increased infection risk

Long-term:

Cushing's syndrome (moon face, central obesity, striae, bruising)
Osteoporosis
HPA axis suppression → adrenal insufficiency on abrupt withdrawal
Proximal myopathy
Cataracts, glaucoma
Avascular necrosis (femoral head)
Growth retardation (children)
Impaired wound healing

ICS-specific:

Oral candidiasis
Dysphonia (hoarseness)

Contraindications

Systemic fungal infections (absolute)
Live vaccines in immunosuppressed patients
Active peptic ulcer, uncontrolled DM, active TB (relative)
Psychosis, severe osteoporosis (relative)
Never abruptly stop after prolonged use — always taper

Drug Interactions

Drug/Class	Effect
NSAIDs	↑GI ulceration risk
Antidiabetics	Antagonism (steroids ↑glucose)
CYP3A4 inducers (rifampicin, phenytoin)	↓steroid levels
CYP3A4 inhibitors (ketoconazole)	↑steroid levels
Diuretics (loop/thiazide)	Additive hypokalemia
Warfarin	Altered anticoagulation (monitor INR)
Live vaccines	Risk of disseminated infection
Theophylline	Synergistic anti-inflammatory via HDAC2

Case 4: A 3-year-old child has fever, signs of acute respiratory viral infections. Objectively: the general condition is satisfactory, the pharynx is hyperemic. Body temperature is 38.8 C. In the lungs without pathology. Station 1 1. Identify the problem (diagnosis): 2. Choose your P-medication for this condition: 3. Dosage form 4. Dosage Station 2 5. Pharmacokinetics of the drug 6. Mechanism of action 7. Write a prescription Station 3 8. Duration of treatment 9. Side effects 10. Contraindications

Finding Sources

Reading File

Now I have sufficient information from the textbooks. Here is the complete structured answer:

Case 4 — Clinical Stations

Station 1

1. Diagnosis: Acute respiratory viral infection (ARVI / URTI) with fever in a 3-year-old child

Fever: 38.8°C
Hyperemic pharynx (pharyngitis)
Lungs clear — no lower respiratory tract involvement
Satisfactory general condition

2. P-Drug of Choice: Paracetamol (Acetaminophen)

Preferred antipyretic/analgesic in children. Safe, well-tolerated, no GI or bleeding risk. Aspirin is contraindicated in children with viral illness (risk of Reye's syndrome). Ibuprofen is an alternative but has more GI side effects.

3. Dosage Form:

Oral syrup / suspension (most suitable for 3-year-old)
Also available as: rectal suppositories (if vomiting), oral tablets/dispersible tablets

4. Dosage:

10–15 mg/kg per dose orally
For a 3-year-old (~14–15 kg): 150–200 mg per dose
Every 4–6 hours as needed
Maximum: 4 doses/day (do not exceed 60 mg/kg/day in children)

Station 2

5. Pharmacokinetics:

Parameter	Detail
Absorption	Rapid; peak plasma concentration within 1 hour, complete absorption in 4 hours
Distribution	Widely distributed; readily crosses blood-brain barrier
Metabolism	Liver: 85–90% conjugated (glucuronidation/sulfation) → non-toxic metabolites excreted in urine; <5% oxidized by CYP2E1 → toxic intermediate NAPQI (neutralized by glutathione at therapeutic doses)
Excretion	Urine (as conjugates)
Half-life	~2–3 hours

6. Mechanism of Action:

Inhibits prostaglandin E2 (PGE2) synthesis in the CNS — via COX-2 inhibition and inhibition of membrane-associated prostaglandin synthase
Acts centrally → antipyretic + analgesic effect
Inactivated peripherally → no peripheral anti-inflammatory effect, no GI/CV/bleeding risks
May also have: COX-3 inhibition, cannabinoid agonist, and NMDA receptor antagonist properties

"Acetaminophen inhibits PGE2 synthesis, leading to antipyresis and analgesia... it is inactivated peripherally so it lacks anti-inflammatory activity and is devoid of systemic GI, CV, and bleeding adverse effects." — Rosen's Emergency Medicine / Lippincott Pharmacology

7. Prescription:

Rp.:  Paracetamoli suspensio 120 mg/5 ml  — 100 ml
D.S.  Give 7.5 ml (= 180 mg) orally every 6 hours
      as needed for fever > 38.5°C.
      Do not exceed 4 doses in 24 hours.
      Shake well before use.

(Paracetamol syrup 120 mg/5 ml is the standard pediatric formulation)

Station 3

8. Duration of Treatment:

3–5 days maximum as antipyretic
Use only when temperature >38.5°C (symptomatic treatment)
Do not use prophylactically; reassess after 3 days if fever persists

9. Side Effects:

At therapeutic doses: Very few — occasionally nausea, rash (rare allergic reaction)
Overdose / chronic supratherapeutic use:
- Hepatotoxicity (centrilobular necrosis) — due to NAPQI accumulation depleting glutathione
- Acute liver failure (potentially fatal)
- Renal tubular necrosis (rare)
Risk of hepatotoxicity ↑ with: malnutrition, fasting, alcoholism, liver disease

10. Contraindications:

Severe hepatic impairment / active liver disease
Known hypersensitivity to paracetamol
Glucose-6-phosphate dehydrogenase (G6PD) deficiency (relative)
Do not combine with other paracetamol-containing products (overdose risk)
Caution in renal impairment (reduce frequency)

Key Point: Aspirin is absolutely contraindicated in children with viral infections — risk of Reye's syndrome (acute encephalopathy + hepatic failure).

Give short and point vise

Case 4 — Short Answers

Station 1

1. Diagnosis: ARVI (Acute Respiratory Viral Infection) with fever + acute pharyngitis

2. P-Drug: Paracetamol (Acetaminophen) (Aspirin — CONTRAINDICATED in children with viral illness → Reye's syndrome)

3. Dosage Form: Oral syrup/suspension 120 mg/5 ml

4. Dosage:

10–15 mg/kg per dose
3-year-old (~15 kg) → 150–200 mg per dose
Every 4–6 hours (max 4 doses/day)

Station 2

5. Pharmacokinetics:

Absorption: Rapid; peak in 1 hour
Distribution: Widely; crosses BBB
Metabolism: Liver — 85–90% glucuronidation/sulfation → non-toxic; <5% via CYP2E1 → NAPQI (toxic, neutralized by glutathione at normal doses)
Excretion: Urine
Half-life: 2–3 hours

6. Mechanism of Action:

Inhibits PGE2 synthesis (COX-2 inhibition) → centrally → antipyresis + analgesia
Inactivated peripherally → no anti-inflammatory effect
Also: COX-3 inhibition, possible NMDA antagonism

7. Prescription:

Rp.: Paracetamoli susp. 120 mg/5 ml — 100 ml
D.S. 7.5 ml orally every 6 h
     when temp >38.5°C
     Max 4 doses/day. Shake before use.

Station 3

8. Duration:

3–5 days maximum
Use only symptomatically (temp >38.5°C)

9. Side Effects:

Therapeutic: minimal (rare rash, nausea)
Overdose: hepatotoxicity (NAPQI depletes glutathione → liver necrosis), renal damage, liver failure

10. Contraindications:

Severe liver disease
Hypersensitivity to paracetamol
G6PD deficiency (relative)
Avoid combining with other paracetamol-containing drugs

CHOOSING A MEDICINE FOR A SPECIFIC CLINICAL SITUATION Case 4: A 3-year-old child has fever, signs of acute respiratory viral infections. Objectively: the general condition is satisfactory, the pharynx is hyperemic. Body temperature is 38.8 C. In the lungs without pathology. Station 1 1. Identify the problem (diagnosis): 2. Choose your P-medication for this condition: 3. Dosage form 4. Dosage Station 2 5. Pharmacokinetics of the drug 6. Mechanism of action 7. Write a prescription Station 3 8. Duration of treatment 9. Side effects 10. Contraindications

Case 4 — ARVI with Fever in a Child

Station 1

1. Diagnosis: Acute Respiratory Viral Infection (ARVI) + Acute Pharyngitis with fever (38.8°C)

2. P-Drug: Paracetamol (Acetaminophen)

Drug of choice for fever in children
⚠️ Aspirin — contraindicated (Reye's syndrome risk)

3. Dosage Form: Oral suspension/syrup — 120 mg/5 ml (Best for 3-year-old; easy to swallow, accurate dosing)

4. Dosage:

10–15 mg/kg/dose
Child ~15 kg → 150–200 mg per dose
Every 4–6 hours as needed
Max 4 doses/24 hours

Station 2

5. Pharmacokinetics:


Absorption	Rapid oral; peak in ~1 h
Distribution	Widely distributed; crosses BBB
Metabolism	Liver: 90% → glucuronidation/sulfation → non-toxic (urine); <5% via CYP2E1 → NAPQI (toxic; detoxified by glutathione at normal doses)
Excretion	Urine
Half-life	2–3 hours

6. Mechanism of Action:

Inhibits COX-2 centrally → ↓PGE2 synthesis → antipyresis + analgesia
Acts centrally (inactivated peripherally → no anti-inflammatory effect, no GI/bleeding side effects)
Additional: COX-3 inhibition, possible NMDA antagonism

7. Prescription:

Rp.:  Paracetamoli susp. 120 mg/5 ml
      fl. 100 ml
D.S.  Give 7.5 ml (180 mg) orally
      every 6 hours when temp >38.5°C.
      Max 4 doses per day.
      Shake well before use.

Station 3

8. Duration of Treatment:

3–5 days maximum
Use only symptomatically (when temp >38.5°C)
Reassess if fever persists beyond 3 days

9. Side Effects:

At therapeutic dose: minimal — rare nausea, allergic rash
Overdose: Hepatotoxicity (NAPQI overwhelms glutathione → centrilobular liver necrosis → liver failure)
Renal tubular damage (rare, high doses)

10. Contraindications:

Severe hepatic impairment
Hypersensitivity to paracetamol
G6PD deficiency (relative)
Do not combine with other paracetamol-containing products (↑ overdose risk)
Caution in malnutrition, alcoholism, renal impairment

Give me short and point vise

Case 4 — Short & Pointed

Station 1

1. Diagnosis: ARVI + Pharyngitis with fever (38.8°C)

2. P-Drug: Paracetamol (Acetaminophen)

3. Dosage Form: Oral suspension 120 mg/5 ml

4. Dose: 10–15 mg/kg → ~150–200 mg every 4–6 h (max 4×/day)

Station 2

5. Pharmacokinetics:

Absorbed rapidly, peak 1 h
Metabolized in liver → 90% non-toxic conjugates
<5% → NAPQI (toxic, neutralized by glutathione)
Excreted in urine; t½ = 2–3 h

6. Mechanism:

Inhibits COX-2 centrally → ↓PGE2 → antipyresis + analgesia
Inactivated peripherally → no anti-inflammatory effect

7. Prescription:

Rp.: Paracetamoli susp. 120 mg/5 ml – 100 ml
D.S. 7.5 ml orally q6h if temp >38.5°C
     Max 4 doses/day. Shake before use.

Station 3

8. Duration: 3–5 days (symptomatic use only)

9. Side Effects:

Therapeutic: minimal (rare rash, nausea)
Overdose: hepatotoxicity → liver failure (NAPQI toxicity)

10. Contraindications:

Severe liver disease
Hypersensitivity
Avoid combining with other paracetamol products
Caution: malnutrition, alcoholism, renal impairment
⚠️ Aspirin contraindicated in children (Reye's syndrome)

This is a shared conversation. Sign in to Orris to start your own chat.